J&J’s Commitment To Diversification Through OTCs Rewarded In Q2
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's second-quarter results show the firm's commitment to broader diversification with the 2006 purchase of Pfizer's consumer business was shrewd. The firm's over-the-counter business countered weak performance in the pharma sector